NCT02049762View on ClinicalTrials.gov

Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Acute Coronary SyndromePlatelet Function and Reactivity TestsNovel P2Y12 Inhibitors

Interventions

DRUG

Aspirin

Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.

Trial Locations (1)

52621

Sheba Medical Center, Tel Litwinsky

All Listed Sponsors

lead

Sheba Medical Center

OTHER_GOV

NCT02049762 - Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy | Biotech Hunter | Biotech Hunter